• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of carbamazepine in the neonate and in the child.

作者信息

Rey E, d'Athis P, de Lauture D, Dulac O, Aicardi J, Olive G

出版信息

Int J Clin Pharmacol Biopharm. 1979 Feb;17(2):90-6.

PMID:422308
Abstract
  1. Pharmacokinetic of carbamazepine were made in 7 new-borns and in 5 children. They were hospitalized for epilepsy and were receiving drugs such as phenobarbital alone or in association with other antiepileptic drugs, but not with carbamazepine. 2. The drug was given by oral route with a mean dose of 17.2 mg.kg-1. 3. The determination of carbamazepine concentration in serum was made by gas liquid chromatography on a 50 microliter sample. 4. A one compartment body model was used to determine the pharmacokinetic constants with first order rate constants for absorption and elimination. 5. Absorption was generally delayed by about half an hour, the maximum concentrations ranging from 3.14 to 10 microgram.ml-1 at 2 and 9 hr after administration. The mean half-life for absorption was 1.42 +/- 0.34 hr. The mean half-life for elimination was 8.76 +/- 0.85 hr. The half-life for elimination was much shorter than those already described even in multiple dosing epileptic adult patients. The pharmacokinetic parameters were used to predict blood levels in chronic treatment in 3 children. The predicted steady state concentrations disagreed with the concentrations measured.
摘要

相似文献

1
Pharmacokinetics of carbamazepine in the neonate and in the child.
Int J Clin Pharmacol Biopharm. 1979 Feb;17(2):90-6.
2
Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.卢非酰胺:癫痫患者的临床药代动力学及浓度-效应关系
Epilepsia. 2008 Jul;49(7):1123-41. doi: 10.1111/j.1528-1167.2008.01665.x.
3
[Role of the pharmacokinetic parameters of carbamazepine in optimizing epilepsy treatment].[卡马西平药代动力学参数在优化癫痫治疗中的作用]
Zh Nevropatol Psikhiatr Im S S Korsakova. 1987;87(9):1327-9.
4
The relative bioavailability and pharmacokinetics of carbamazepine.卡马西平的相对生物利用度和药代动力学。
Int J Clin Pharmacol Biopharm. 1978 Aug;16(8):377-9.
5
Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.基于塞尔维亚癫痫患者临床数据的卡马西平药代动力学建模
Methods Find Exp Clin Pharmacol. 2008 Nov;30(9):707-13. doi: 10.1358/mf.2008.30.9.1303589.
6
Carbamazepine and carbamazepine-10,11- epoxide during pregnancy and postnatal period in epileptic mother and their nursed infants: pharmacokinetics and clinical effects.
Pediatr Pharmacol (New York). 1983;3(3-4):199-208.
7
[Effect of (+)-catechin on the pharmacokinetics of carbamazepine in rabbits].
Arzneimittelforschung. 1982;32(11):1440-2.
8
The epoxide of carbamazepine.卡马西平的环氧化物。
Clin Exp Neurol. 1979;16:95-104.
9
Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation.多次服用缓释制剂后卡马西平和卡马西平-环氧化物药代动力学的再分析
J Pharm Pharm Sci. 2002 May-Aug;5(2):169-75.
10
Linezolid pharmacokinetics in pediatric patients: an overview.利奈唑胺在儿科患者中的药代动力学:综述。
Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S153-7. doi: 10.1097/01.inf.0000086954.43010.63.

引用本文的文献

1
Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study.将生物相关儿科溶出度方法学整合到 PBPK 建模中,以预测儿科人群中仿制药的体内性能和生物等效性:卡马西平案例研究。
AAPS J. 2023 Jun 29;25(4):67. doi: 10.1208/s12248-023-00826-1.
2
Investigating Oral Absorption of Carbamazepine in Pediatric Populations.研究卡马西平在儿科人群中的口服吸收情况。
AAPS J. 2017 Nov;19(6):1864-1877. doi: 10.1208/s12248-017-0149-6. Epub 2017 Oct 2.
3
A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures.
难治性癫痫新生儿抗癫痫药物药代动力学的系统评价。
J Pediatr Pharmacol Ther. 2012 Jan;17(1):31-44. doi: 10.5863/1551-6776-17.1.31.
4
Neonatal exposure to drugs in breast milk.新生儿通过母乳接触药物。
Pharm Res. 2004 Apr;21(4):555-66. doi: 10.1023/b:pham.0000022401.14710.c5.
5
Diagnosis and treatment of epilepsy in children and adolescents.儿童及青少年癫痫的诊断与治疗
Drugs. 1996 Mar;51(3):399-414. doi: 10.2165/00003495-199651030-00005.
6
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.抗癫痫药物在儿科患者中的临床药代动力学。第二部分。苯妥英、卡马西平、舒噻美、拉莫三嗪、氨己烯酸、奥卡西平和非氨酯。
Clin Pharmacokinet. 1995 Nov;29(5):341-69. doi: 10.2165/00003088-199529050-00004.
7
Saliva carbamazepine levels in children before and during multiple dosing.多次给药前后儿童唾液中卡马西平的水平。
Br J Clin Pharmacol. 1982 May;13(5):647-51. doi: 10.1111/j.1365-2125.1982.tb01431.x.
8
Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics.孕期及哺乳期的抗惊厥药。经胎盘、母体及新生儿的药代动力学。
Clin Pharmacokinet. 1982 Nov-Dec;7(6):508-43. doi: 10.2165/00003088-198207060-00003.
9
Anticonvulsants in the newborn period.新生儿期的抗惊厥药。
Indian J Pediatr. 1985 Sep-Oct;52(418):513-26. doi: 10.1007/BF02751028.
10
Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.卡马西平和卡马西平 - 10,11 - 环氧化物的临床药代动力学及药理作用。最新进展。
Clin Pharmacokinet. 1986 May-Jun;11(3):177-98. doi: 10.2165/00003088-198611030-00001.